Boston — Ratio Therapeutics has appointed Kenan Turnacioglu, Ph.D., to its Board of Directors, adding more than two decades of experience in healthcare investing, biotechnology company building, oncology and corporate governance.
Ratio is a clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment.
“Kenan brings a rare combination of scientific depth, long-term healthcare-investing experience and firsthand perspective helping build and govern innovative life sciences companies,” said Jack Hoppin, Ph.D., Chairman and Chief Executive Officer of Ratio. “We are incredibly enthusiastic to welcome his encyclopedic knowledge of the pharmaceutical industry to our Board.”
Turnacioglu is a healthcare investor and biotechnology board leader with experience in oncology, precision medicine and data-enabled life sciences.
He currently serves on the boards of Immunai, Massive Bio and Sentonix. He previously served as a General Partner and member of the Investment Committee at Catalio Capital Management.
Turnacioglu also co-founded PointState Capital Management in 2011, where he managed healthcare and consumer portfolios and investment teams. Earlier in his career, he managed healthcare investments at Duquesne Capital Management and worked as a biotechnology research analyst at Credit Suisse.
He has previously served on the boards of Paige AI, StemCentrx, Agensys and NYU Langone Cancer Center.
“Ratio has assembled an experienced team, a differentiated set of technology platforms and a compelling opportunity to advance precision radiopharmaceuticals for cancer patients,” Turnacioglu said. “I am particularly excited by the company’s focus on addressing the practical challenges that shape the potential of radiopharmaceutical therapies, including drug delivery, tumor uptake and manufacturability.”
Turnacioglu earned a B.A. from Rutgers University and a Ph.D. from the University of Pennsylvania and completed postdoctoral training at Johns Hopkins University.
